ASH 2023 | Induction & maintenance therapy in elderly patients with MCL: insights from the MCL-R2 Elderly trial
Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, presents findings from the double-randomized MCL-R2 Elderly clinical trial (EUDRACT: 2012-002542-20) comparing two immunochemotherapy induction regimens (8 cycles of 3-weekly R-CHOP versus 6 cycles of alternating 3-weekly R-CHOP and 4-weekly R-HAD), followed by maintenance treatment with rituximab or rituximab plus lenalidomide in elderly patients with previously untreated mantle cell lymphoma (MCL). There were no significant differences in treatment outcomes between the two immunochemotherapy regimens. However, there was a significant increase in progression-free survival (PFS) when lenalidomide was included in maintenance treatment, although this was accompanied by increased toxicity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Beigene, Abbvie, Eli Lilly and Company, Incyte, Autolus, Janssen, KITE, Loxo Oncology, AstraZeneca, Roche, Gilead
Honoraria: Beigene, Abbvie, Eli Lilly and Company, Janssen, KITE, Loxo Oncology, AstraZeneca, Roche, Gilead
Membership on Board of Directors/Advisory Committee: Beigene, Abbvie, Incyte, KITE, AstraZeneca, Roche, Gilead, Loxo Lilly
Research Funding: Beigene, AstraZeneca, Secura Bio
Speakers Bureau: Beigene, Abbvie, Eli Lilly and Company, Incyte, Janssen, KITE, Loxo Oncology, AstraZeneca, Roche, Gilead, Loxo Lilly, PeerView, Medscape
Other: Loxo Oncology
